<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713490</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-331</org_study_id>
    <nct_id>NCT02713490</nct_id>
  </id_info>
  <brief_title>Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately&#xD;
      140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine&#xD;
      HCl (10-15 mg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On Day 0, eligible subjects will be randomized 1:1 to two treatment groups. Subjects in Group&#xD;
      1 will receive local infiltration analgesia (LIA) with EXPAREL 266 mg in 20 mL admixed with&#xD;
      bupivacaine hydrochloride (HCl) 0.5% in 20 mL and expanded in volume with 80 mL normal saline&#xD;
      (total volume of 120 mL). Subjects in Group 2 will receive LIA with bupivacaine HCl 0.5% in&#xD;
      20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL). Investigators&#xD;
      will use their usual surgical technique to perform the TKA.&#xD;
&#xD;
      Study drug will be administered using six 20 cc syringes with 22-gauge needles prior to wound&#xD;
      closure. Each stick should deliver approximately 1-1.5 cc to the intended area. The tissue&#xD;
      should visibly expand with minimal leakage. Study drug should be injected in the prescribed&#xD;
      locations based on the areas of highest nerve density.&#xD;
&#xD;
      Infiltration Technique&#xD;
&#xD;
      Prior to cementation&#xD;
&#xD;
      Syringe #1: Posterior capsule (8-10 sticks medial and 8-10 sticks lateral).&#xD;
&#xD;
      Syringe #2: Femur medial and lateral periosteum, posterior periosteum,&#xD;
      suprapatellar/quadriceps tendon (20 sticks).&#xD;
&#xD;
      Syringe #3: Tibia fat pad (5 sticks); pes anserinus, medial collateral ligament, and gutter&#xD;
      (15 sticks).&#xD;
&#xD;
      Syringe #4: Circumferential periosteum (15-20 sticks).&#xD;
&#xD;
      After cementation&#xD;
&#xD;
      Syringe #5: Midline quadriceps tendon (10 sticks); retinaculum, medial gutter, femoral to&#xD;
      tibia (10 sticks).&#xD;
&#xD;
      Syringe #6: Lateral gutter, femoral to tibial (10 sticks); subcutaneous/closure (10 sticks).&#xD;
&#xD;
      In addition to LIA, all study participants will receive a standardized approach for managing&#xD;
      postsurgical pain that includes a scheduled multimodal pain regimen including adjunctive&#xD;
      analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), and rescue analgesics as needed.&#xD;
&#xD;
      Postsurgical clinical assessments will include pain intensity scores using a 10-cm visual&#xD;
      analog scale (VAS); overall benefit of analgesia score (OBAS) questionnaire; total&#xD;
      postsurgical opioid consumption; physical therapy assessment; nurse's satisfaction with&#xD;
      overall analgesia; and discharge readiness. Adverse events (AEs) will be recorded from the&#xD;
      time the informed consent form is signed through postsurgical Day 29.&#xD;
&#xD;
      Postsurgical health economic outcome assessments will include hospital length of stay (LOS),&#xD;
      use of skilled nursing facility, outpatient physical therapy use, hospital readmissions, and&#xD;
      use of other health services following discharge (phone calls related to postsurgical pain,&#xD;
      unscheduled visits related to postsurgical pain, and visits to emergency department) through&#xD;
      postsurgical Day 29.&#xD;
&#xD;
      A follow-up visit will be scheduled for all subjects on postsurgical Day 14. A follow-up&#xD;
      phone call will be made on postsurgical Day 29 to all subjects who received study drug to&#xD;
      assess for AEs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 18, 2016</start_date>
  <completion_date type="Actual">February 8, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours</measure>
    <time_frame>From 12-48 hours</time_frame>
    <description>AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, &quot;How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Postsurgical Opioid Consumption Through 48 Hours</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Opioid-free Subjects at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Rescue in the First 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to first opioid rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Benefit of Analgesia Score at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The overall benefit of analgesic score (OBAS) comprises seven questions to assess pain intensity, adverse effects, and patients' satisfaction with analgesia (eg, &quot;Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain&quot;). Overall scores ranged between 0- 28. OBAS measures patients' benefit from postoperative pain therapy. A lower composite score indicates greater benefit from the therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>EXPAREL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL</intervention_name>
    <description>EXPAREL and bupivacaine HCl</description>
    <arm_group_label>EXPAREL</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Single dose of bupivacaine HCl 0.5%</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>bupivacaine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, at least 18 years of age at screening.&#xD;
&#xD;
          2. Scheduled to undergo primary, unilateral, tricompartmental TKA under spinal&#xD;
             anesthesia.&#xD;
&#xD;
          3. Primary indication for TKA is degenerative osteoarthritis of the knee.&#xD;
&#xD;
          4. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.&#xD;
&#xD;
          5. Female subjects must be surgically sterile; or at least 2 years postmenopausal; or&#xD;
             have a monogamous partner who is surgically sterile; or practicing double-barrier&#xD;
             contraception; or practicing abstinence (must agree to use double-barrier&#xD;
             contraception in the event of sexual activity); or using an insertable, injectable,&#xD;
             transdermal, or combination oral contraceptive approved by the FDA for greater than 2&#xD;
             months prior to screening and commit to the use of an acceptable form of birth control&#xD;
             for the duration of the study and for 30 days after completion of the study.&#xD;
&#xD;
          6. Able to provide informed consent, adhere to the study visit schedule, and complete all&#xD;
             study assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently pregnant, nursing, or planning to become pregnant during the study or within&#xD;
             1 month after study drug administration.&#xD;
&#xD;
          2. History of previous prior contralateral TKA or open knee surgery on the knee being&#xD;
             considered for TKA. Prior arthroscopy is permitted.&#xD;
&#xD;
          3. Planned concurrent surgical procedure (e.g., bilateral TKA).&#xD;
&#xD;
          4. Undergoing unicompartmental TKA or revision TKA.&#xD;
&#xD;
          5. Concurrent painful physical condition that may require analgesic treatment (such as an&#xD;
             NSAID or opioid) in the postsurgical period for pain that is not strictly related to&#xD;
             the knee surgery and which may confound the postsurgical assessments (e.g.,&#xD;
             significant pain from other joints including the non-index knee joint, chronic&#xD;
             neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).&#xD;
&#xD;
          6. Comorbidity impacting current physical function of Investigator opinion that it may&#xD;
             impact postsurgical rehabilitation.&#xD;
&#xD;
          7. Allergy, hypersensitivity, or contraindication to any of the study medications (i.e.,&#xD;
             bupivacaine, pregabalin, acetaminophen/paracetamol, celecoxib, oxycodone, morphine,&#xD;
             hydromorphone, or tranexamic acid).&#xD;
&#xD;
          8. Use of any of the following medications within the times specified before surgery:&#xD;
             long-acting opioid medication or NSAIDs (except for low-dose aspirin used for&#xD;
             cardioprotection) within 3 days, or any opioid medication within 24 hours.&#xD;
&#xD;
          9. Initiation of treatment with any of the following medications within 1 month of study&#xD;
             drug administration or if the medication(s) are being given to control pain: selective&#xD;
             serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors&#xD;
             (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is&#xD;
             taking one of these medications for a reason other than pain control, he or she must&#xD;
             be on a stable dose for at least 1 month prior to study drug administration.&#xD;
&#xD;
         10. Current use of systemic glucocorticosteroids within 1 month of enrollment in this&#xD;
             study.&#xD;
&#xD;
         11. Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration.&#xD;
&#xD;
         12. History of coronary or vascular stent placed within the past 3 months (may be extended&#xD;
             to 1 year if medically indicated per physician discretion).&#xD;
&#xD;
         13. Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial&#xD;
             infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if&#xD;
             medically indicated per physician discretion).&#xD;
&#xD;
         14. Rheumatoid or inflammatory arthritis or disease.&#xD;
&#xD;
         15. Severely impaired renal or hepatic function (e.g., serum creatinine level &gt;2 mg/dL&#xD;
             [176.8 µmol/L], blood urea nitrogen level &gt;50 mg/dL [17.9 mmol/L], serum aspartate&#xD;
             aminotransferase [AST] level &gt;3 times the upper limit of normal [ULN], or serum&#xD;
             alanine aminotransferase [ALT] level &gt;3 times the ULN.)&#xD;
&#xD;
         16. Any neurologic or psychiatric disorder that might impact postsurgical pain or&#xD;
             interfere with study assessments.&#xD;
&#xD;
         17. Malignancy in the last 2 years, per physician discretion.&#xD;
&#xD;
         18. History of misuse, abuse, or dependence on opioid analgesics, other prescription&#xD;
             drugs, illicit drugs, or alcohol.&#xD;
&#xD;
         19. Failure to pass the alcohol breath test or urine drug screen.&#xD;
&#xD;
         20. Body weight &lt;50 kg (110 pounds) or a body mass index &gt;40 kg/m2.&#xD;
&#xD;
         21. Previous participation in an EXPAREL study.&#xD;
&#xD;
         22. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Jones, MD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Joint Restoration</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Orthopaedics &amp; Sports</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital, Northwestern Medicine</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Hospital for Joint Disease</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital/Northwell Health Orthopaedic Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Orthopaedics Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Orthopaedics and Sports Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Medical Center, Plano Orthopedics Sports Medical &amp; Spine Center</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah University Orthopedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02713490/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02713490/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between April 18, 2016 and February 8, 2017 at 16 sites in the United States</recruitment_details>
      <pre_assignment_details>A total of 167 patients were screened; there were 27 screen failures, including 2 patients who were randomized in error to the EXPAREL 266 mg + bupivacaine hydrochloride (HCl) group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EXPAREL 266 mg + Bupivacaine HCl</title>
          <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine HCl</title>
          <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received study drug, with analysis by actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>EXPAREL</title>
          <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine</title>
          <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="8.61"/>
                    <measurement group_id="B2" value="65.8" spread="7.21"/>
                    <measurement group_id="B3" value="65.8" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.395" spread="5.805"/>
                    <measurement group_id="B2" value="31.311" spread="5.189"/>
                    <measurement group_id="B3" value="31.857" spread="5.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS pain score</title>
          <description>Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, &quot;How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now.&quot;</description>
          <population>Two patients in the EXPAREL 266 mg + bupivacaine HCl group did not have VAS measurements entered in the database.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.91" spread="2.120"/>
                    <measurement group_id="B2" value="1.89" spread="2.241"/>
                    <measurement group_id="B3" value="1.90" spread="2.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Association of Anesthesiologists classification</title>
          <description>American Society of Anesthesiologists (ASA) classification was determined by physicians using the ASA Physical Status Classification System which assesses the patient's pre-anesthesia medical co-morbidities. ASA 1 patients would be considered a normal, healthy patient. ASA 2 is a patient with mild systemic disease (eg, smoker, well controlled diabetes or high blood pressure (HBP)). ASA 3 is a patient with severe systemic disease (eg poorly controlled diabetes or HBP). ASA 4 is a patient with severe systemic disease that is a constant threat to life (eg, recent myocardial infarction, stroke).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Left</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours</title>
        <description>AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, &quot;How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now.&quot;</description>
        <time_frame>From 12-48 hours</time_frame>
        <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours</title>
          <description>AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, &quot;How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now.&quot;</description>
          <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
          <units>cm*hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.523" spread="10.786"/>
                    <measurement group_id="O2" value="208.407" spread="10.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0381</p_value>
            <method>ANOVA</method>
            <param_type>LSMD</param_type>
            <param_value>-26.884</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.608</ci_lower_limit>
            <ci_upper_limit>2.841</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Postsurgical Opioid Consumption Through 48 Hours</title>
        <description>Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours</description>
        <time_frame>0-48 hours</time_frame>
        <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Postsurgical Opioid Consumption Through 48 Hours</title>
          <description>Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours</description>
          <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.321" spread="6.684"/>
                    <measurement group_id="O2" value="80.328" spread="33.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>ANOVA</method>
            <param_type>LSM treatment ratio</param_type>
            <param_value>0.203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.631</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Opioid-free Subjects at 48 Hours</title>
        <time_frame>48 hours</time_frame>
        <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Opioid-free Subjects at 48 Hours</title>
          <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment difference</param_type>
            <param_value>0.098</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0284</ci_lower_limit>
            <ci_upper_limit>0.1685</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Rescue in the First 48 Hours</title>
        <description>Time to first opioid rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).</description>
        <time_frame>48 hours</time_frame>
        <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Rescue in the First 48 Hours</title>
          <description>Time to first opioid rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).</description>
          <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
          <units>h</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" lower_limit="1.083" upper_limit="3.233"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.600" upper_limit="1.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.125" lower_limit="3.333" upper_limit="6.133"/>
                    <measurement group_id="O2" value="2.917" lower_limit="2.083" upper_limit="3.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Third quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.667" lower_limit="6.250" upper_limit="31.083"/>
                    <measurement group_id="O2" value="7.200" lower_limit="4.00" upper_limit="12.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis applies to the overall distribution of time to first opioid rescue, estimated from Kaplan-Meier analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0230</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Benefit of Analgesia Score at 48 Hours</title>
        <description>The overall benefit of analgesic score (OBAS) comprises seven questions to assess pain intensity, adverse effects, and patients' satisfaction with analgesia (eg, &quot;Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain&quot;). Overall scores ranged between 0- 28. OBAS measures patients' benefit from postoperative pain therapy. A lower composite score indicates greater benefit from the therapy.</description>
        <time_frame>48 hours</time_frame>
        <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Benefit of Analgesia Score at 48 Hours</title>
          <description>The overall benefit of analgesic score (OBAS) comprises seven questions to assess pain intensity, adverse effects, and patients' satisfaction with analgesia (eg, &quot;Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain&quot;). Overall scores ranged between 0- 28. OBAS measures patients' benefit from postoperative pain therapy. A lower composite score indicates greater benefit from the therapy.</description>
          <population>Efficacy population: all participants who received study drug and underwent the surgery, with analysis based on randomized treatment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.08"/>
                    <measurement group_id="O2" value="4.6" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4285</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to postsurgical day 29</time_frame>
      <desc>An AE was defined as any untoward medical occurrence associated with the use of a drug in humans whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (eg, abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug without any judgment about causality. Serious AEs were defined as per clinicaltrials.gov.&#xD;
Note that 71 subjects were randomized into the EXPAREL arm, but only 70 subjects received EXPAREL.</desc>
      <group_list>
        <group group_id="E1">
          <title>EXPAREL</title>
          <description>Local infiltration analgesia with EXPAREL (bupivacaine liposome injectable suspension) 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL and expanded with 80 mL normal saline</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine</title>
          <description>Local infiltration analgesia with bupivacaine HCl 0.5% 20 mL expanded with 100 mL normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood osmolarity decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pacira Medical Information</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>1-855-793-9727</phone>
      <email>MedInfo@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

